S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES). Amendment 3 7.15.18

Details
Age
Adult
Type of Study
Prevention
Scope
National
Locations
Cherry Creek Medical Center
Memorial Hospital Central
University of Colorado Hospital
Principal Investigator

Martin Mccarter, MD
Study ID
Protocol Number: 15-1590
More information available at ClinicalTrials.gov: NCT01349881
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers